Reading a tTG-IgA result: cutoffs, borderline results and lab differences
Short answer
A tTG-IgA number is read against the cutoff on the report it came from, because assays are not standardised1, 8 and, as the Gluten Intolerance Group puts it, every lab has slightly different “normal” levels2. Read it in this order:
- Find the cutoff, or upper limit of normal, printed on your own report: the guidelines tie the upper limit of normal to the assay3, and the Gluten Intolerance Group says every lab has slightly different “normal” levels2.
- See how many times above it your number sits: guidelines describe results as multiples of the upper limit of normal for the assay, with one line at 10 times3, 4.
- Read the rest of the report with it: ACG says total IgA should be measured at the same time if IgA deficiency has not been tested before5, and Coeliac UK says IgA deficiency gives a false negative result on an IgA antibody test6.
- What follows is the clinician’s call. Below 10 times, ESPGHAN says children should have biopsies; at or above, ESPGHAN says a no-biopsy diagnosis may be applied if the family agrees and a second blood sample tests positive for EMA-IgA7, 4.
Part of Celiac diagnosis, testing and gluten sensitivity, 25 guides

Key points
- Labs do not share one normal range: the Gluten Intolerance Group says each has slightly different “normal” levels2, and ESPGHAN says work is needed to establish a common standard that would allow direct comparison between tests8.
- The line the guidelines use for the no-biopsy route is 10 times the upper limit of normal; ACG writes it as above 10 times, ESPGHAN as at or above9, 4.
- ACG calls a positive serological test supportive of the diagnosis10, and notes that diagnostic accuracy varies considerably between laboratories49.
- A negative result can be wrong when someone was not eating gluten at the time of the blood test11.
- NIDDK says doctors do not recommend starting a gluten-free diet before diagnostic testing, because it can affect test results12.
Where the cutoff sits on your report
ACG’s guideline says serologic testing should consist of measuring TTG IgA5, and ESPGHAN calls it the most appropriate primary test for children, using the abbreviation TGA-IgA13. Look on your report for the reference range or cutoff the lab gives next to the result.
That cutoff is the lab’s own. Coeliac UK’s page for clinicians, listing the British Society of Gastroenterology’s recommendations, gives the no-biopsy threshold for adults as 10 times the upper limit of normal “for the assay”3, and a Gluten Intolerance Group article on diagnosis notes that every lab has slightly different “normal” levels for the test2.
So the first thing to read is the lab’s cutoff or upper limit of normal, and the second is how many times above it your number sits. This page cannot give a range that fits every lab, and it does not interpret anyone’s result.
Why one lab’s number cannot be compared with another’s
A 2012 article in the Journal of Pediatric Gastroenterology and Nutrition, about the 2012 ESPGHAN guidance, said that the lack of standardisation between assays makes it difficult to harmonise results between centres, because each assay shows different performance characteristics1.
The 2020 ESPGHAN guideline points the same way. It notes inter-laboratory and inter-test variability14, describes one study that “also demonstrated high inter-test and inter-laboratory variability at these lower ranges”15, and says work is needed to establish a common standard that would allow direct comparison between the tests8.
ACG’s text agrees that the diagnostic accuracy of serology varies considerably between laboratories49, and it lists as an open research question whether an optimal cutoff exists for adults across a range of commercial laboratories16.
Coeliac UK’s clinician page, in the same list of BSG recommendations, says laboratories that use the 10xULN threshold should take part in external tTG quality assurance, for example UK-NEQAS or a local audit17.
Negative, borderline, positive: what the labels mean
Check what your own report calls each range. Neither guideline quoted on this page uses “weak positive” as a grade of a tTG-IgA result18, 19; they split results by multiples of the upper limit of normal instead4, 9.
ESPGHAN’s algorithm for children does use the word “borderline”, in notes that tell the clinician to check the value against the cut-off, repeat the test if it is questionable or borderline20, and, for a borderline positive, to confirm sufficient gluten intake and consider re-testing tTG-IgA (TGA-IgA) and EMA21. The notes give no number for “borderline”.
| Term | Source | What the source says |
|---|---|---|
| Upper limit of normal (ULN) | Coeliac UK, ESPGHAN | The reference point for the assay; a result is described as a multiple of it3, 4. |
| Borderline positive | ESPGHAN algorithm notes | Confirm sufficient gluten intake and consider re-testing21. |
| Lower titers (below 10 times ULN) | ESPGHAN | Children with a positive result at this level should undergo biopsies7. |
| High-level (above 10 times ULN in ACG; at or above in ESPGHAN) | ACG, ESPGHAN | The basis of the no-biopsy route in children, with a positive EMA in a second blood sample22, 4. |
What “10 times the upper limit of normal” changes
The guidelines treat a result above (ACG) or at or above (ESPGHAN) 10 times the upper limit of normal differently from a lower positive4, 9. The rule depends on the age group and on whose guidance is being followed.
| Guidance and group | When biopsy can be left out | Otherwise (below the line) |
|---|---|---|
| ESPGHAN 2020, children (Europe) | tTG-IgA (TGA-IgA) at or above 10 times ULN, a positive EMA-IgA in a second blood sample, and the family agrees4. | At least 4 biopsies from the distal duodenum and at least 1 from the bulb23. |
| ACG 2023, children (US) | ACG suggests high-level TTG IgA (above 10 times ULN) with a positive EMA in a second blood sample9, and only if the family agrees22. | ACG recommends EGD with multiple duodenal biopsies in both children and adults with suspected celiac disease24. |
| ACG 2023, adults (US) | In symptomatic adults unwilling or unable to have upper GI endoscopy, the same criteria may be considered after the fact as a diagnosis of likely celiac disease9. | A patient with a raised TTG IgA should proceed to EGD with duodenal biopsy25. |
| British Society of Gastroenterology (BSG) 2026, adults (UK), as summarised by Coeliac UK | Symptomatic adults assessed in secondary care, with tTG-IgA at or above 10 times ULN for the assay, no other reason for an endoscopy, and a shared decision with the patient26. | Coeliac UK says most adults will still need an endoscopy and biopsy27. |
Coeliac UK’s page for patients says that around 20-30% of adults with symptoms associated with undiagnosed coeliac disease have antibody levels that high28, and that for children a biopsy may not be necessary at that level when a second blood test is also positive29.
In the UK, Coeliac UK says the revised 2026 BSG guidelines formally recognise that some adults may be diagnosed from a single blood test, when assessed by a gastroenterologist and in discussion with the patient30.
Cautions the guidelines attach to the line
- ESPGHAN says positive results below 10 times ULN are prone to technical error because of inter-laboratory and inter-test variability, so they are not sufficient for the no-biopsy approach14.
- ESPGHAN also says that for a diagnosis without biopsies only tests with calibrator curve-based calculation, and with the 10× ULN value inside their measurement range, should be used31.
- ACG names the absence of standardization of TTG assays, and the risk of misdiagnosis when the strict criteria are not followed, as limits of the approach32.
- ESPGHAN adds that in asymptomatic children the positive predictive value of a high result may be lower than in symptomatic children33.
Adults: a 2024 meta-analysis found that the positive predictive value of the no-biopsy approach was 65%, 88%, 95% and 99% if celiac disease prevalence was 1%, 4%, 10% and 40% respectively34. Its authors suggested that selected adults with tTG-IgA at or above 10 times ULN and a moderate to high pretest probability of celiac disease could be diagnosed without endoscopy and biopsy35. The figures show that the positive predictive value of the no-biopsy approach rises with how common celiac disease is in the group tested34.
What a lower positive usually leads to
ACG’s text says patients with a raised TTG IgA level should proceed to EGD with duodenal biopsy25. For children, ESPGHAN says positive results below 10 times ULN should be followed by biopsies7. A 2024 review in Clinical Chemistry says that people with low positive tTG-IgA levels need a biopsy to establish a diagnosis36.
In the UK, Coeliac UK says a positive blood test leads to referral to a gastroenterologist, and that a biopsy is usually carried out to confirm the diagnosis, though in some cases both adults and children can be diagnosed from blood tests without one37.
This is how the sources describe a positive result. ACG calls a positive serological test supportive of the diagnosis10. The Gluten Intolerance Group says raised antibodies do not always mean celiac disease, because they could signal other autoimmune issues38, and that a false positive could reflect an infection or inflammatory bowel disease, with some medications also able to raise tTG-IgA levels39.
Total IgA, EMA and the other lines on the same report
Total IgA
ACG’s text says serologic testing should measure TTG IgA on a regular, gluten-containing diet and, if the patient has not previously been tested for IgA deficiency, total IgA at the same time5. Coeliac UK’s clinician page says people with IgA deficiency will have a false negative serological result when tested for IgA antibody, which may lead to a missed diagnosis6.
When IgA deficiency is present, ACG says an IgG serology (commonly DGP and/or TTG) should be measured40, and ESPGHAN says that for children with low total IgA an IgG-based test (DGP, EMA or TGA) should be done as a second step41. ESPGHAN notes that the 10× ULN cut-off is not validated for TGA-IgG42.
EMA in a second sample
In the no-biopsy route, EMA-IgA is tested in a second blood sample4. ESPGHAN says this aims at avoiding mislabelling of samples or technical errors, and at confirming coeliac auto-immunity with another test assay of high specificity43.
A negative result, and why gluten intake matters
NIDDK says doctors do not recommend starting a gluten-free diet before diagnostic testing because it can affect test results12. Coeliac UK says the same, and adds that reducing gluten before testing will affect results44.
Coeliac UK also says it is possible to have a negative blood test and still have coeliac disease, and that a person who was not eating gluten at the time may have received an inaccurate result11.
ACG’s text says a negative TTG IgA in patients without IgA deficiency has a high negative predictive value if the pretest probability is low or moderate45, and that when pretest probability is high, EGD with duodenal biopsy should be considered even with a negative serology46.
Coeliac UK’s clinician page says a gluten-free diet should not be started until a specialist has confirmed the diagnosis, even if a serological test is positive47.
Repeat tests and results from a different lab
The sources give repeat tests different jobs. ESPGHAN’s notes say to repeat the test if a value is questionable or borderline, and that there is no need to retest if a validated assay with a calibration curve was used20. ESPGHAN says its no-biopsy recommendation rests on a second serum sample, tested for EMA-IgA, taken on a separate occasion on a gluten-containing diet48.
A result from a new lab can look different. The Gluten Intolerance Group says every lab has slightly different “normal” levels, so a patient tested in a new place could see discrepancies in the numbers2.
Questions people ask
Does a positive result below 10 times the upper limit mean celiac disease is unlikely?
The sources quoted here do not say that. ESPGHAN says children with positive results under 10 times the upper limit should undergo biopsies, to decrease the risk of a false positive diagnosis7, and ACG says patients with a raised TTG IgA level should proceed to EGD with biopsy25.
More in Celiac diagnosis, testing and gluten sensitivity
Celiac Blood Tests: What tTG-IgA, Total IgA, DGP and EMA Each CheckWhat tTG-IgA, total IgA, EMA and DGP check, why total IgA is drawn with tTG-IgA, when back-up tests are used, and why gluten stays in the diet first.
Low total IgA and celiac disease: which tests guidelines name insteadWhy very low total IgA can hide celiac disease on the usual tTG-IgA test, which IgG-based tests guidelines name instead, and what a clinic should cover.
Positive celiac blood test but a normal biopsy: what doctors call potential celiac diseaseWhat celiac guidelines say when antibodies are positive but the biopsy looks normal: potential celiac disease, other causes, and the follow-up described.
Seronegative celiac disease: when antibodies are negative but the biopsy is notWhat seronegative celiac disease means, which checks come before the label (total IgA, gluten intake, other causes) and what published series report.
Marsh 1 on a biopsy report with negative celiac blood tests: what the guidelines sayWhat Marsh 1 or lymphocytic duodenosis means when celiac antibodies are negative, which other causes sources list, and what guidelines say comes next.
Reading a celiac biopsy report: Marsh grades and villous atrophyWhat villous atrophy, lymphocyte counts and Marsh 0 to 3c on a celiac biopsy report describe, and why guidelines read them with blood tests.
All 25 guides in Celiac diagnosis, testing and gluten sensitivity
Related guides
Diagnosing celiac disease in children without a biopsy: what the ESPGHAN guideline requiresThe conditions ESPGHAN sets for diagnosing celiac disease in a child without a biopsy, what must be confirmed first, and how US guidance differs.
Celiac genetic testing: what HLA-DQ2 and DQ8 results can and cannot tell youWhat HLA-DQ2 and DQ8 typing checks for, how NIDDK, ACG, ESPGHAN and WGO read a negative or positive result, and where the guidelines place the test.
The repeat biopsy in celiac disease: when guidelines suggest one and what the result meansWhen guidelines suggest a repeat biopsy in celiac disease, what Marsh grades on the report mean, and what the guidelines say follows if damage persists.
Sources
- [1] PubMed (J Pediatr Gastroenterol Nutr, 2012), ESPGHAN guidance on coeliac disease 2012: multiples of ULN for decision making do not harmonise assay performance across centres (Egner et al.), checked Nov 17, 2026.
- [2, 38, 39] Gluten Intolerance Group, 3 Steps to a Celiac Disease Diagnosis, checked Nov 17, 2026.
- [3, 6, 17, 26, 27, 30, 47] Coeliac UK, How to test adults (healthcare professionals), checked Nov 17, 2026.
Read on 2026-11-17: the list headed “When can a no biopsy pathway be considered in adults?” names symptomatic adults being assessed in secondary care settings; IgA tTG at or above 10 times the upper limit of normal (ULN) for the assay; no other reasons to have an endoscopy; and a pathway that is optional and adopted only after shared decision making with the patient.
- [4, 7, 8, 13, 14, 15, 19, 20, 21, 23, 31, 33, 41, 42, 43, 48] ESPGHAN (Journal of Pediatric Gastroenterology and Nutrition), European Society Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for Diagnosing Coeliac Disease 2020 (Husby et al.), checked Nov 17, 2026.
Searched the full text on 2026-11-17 for “weak”: no use of “weak positive” as a grade of a tTG-IgA result. Its one use of “weak” is “a weak association between EoE and CD”.
- [5, 9, 10, 16, 18, 22, 24, 25, 32, 40, 45, 46, 49] American College of Gastroenterology (American Journal of Gastroenterology), ACG Clinical Guidelines Update: Diagnosis and Management of Celiac Disease (Rubio-Tapia et al., 2023), checked Nov 17, 2026.
Searched the full text on 2026-11-17 for “weak”: no use of “weak positive” as a grade of a tTG-IgA result. Its one use of “weak” grades the strength of a recommendation.
- [11, 28, 29, 37, 44] Coeliac UK, Testing for Coeliac Disease: Blood Tests and Biopsy, checked Nov 17, 2026.
- [12] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Diagnosis of Celiac Disease, checked Nov 17, 2026.
- [34, 35] PubMed (Gastroenterology, 2024), Accuracy of the No-Biopsy Approach for the Diagnosis of Celiac Disease in Adults: A Systematic Review and Meta-Analysis (Shiha et al.), checked Nov 17, 2026.
- [36] PubMed (Clinical Chemistry, 2024), Laboratory Testing for Celiac Disease: Clinical and Methodological Considerations (Husby et al.), checked Nov 17, 2026.